New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
News|Articles|October 1, 2026
Clinical trial news in pediatrics: September 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Advertisement
Advertisement
September 2026's pediatric clinical trial readouts clustered heavily around growth and metabolic disorders. Three skeletal dysplasia programs — two in achondroplasia and one in hypochondroplasia — reported growth-velocity gains, while two GLP-1-class agents posted substantial BMI reductions in adolescents and in children as young as 6. Rare pediatric epilepsy, kidney disease, and eosinophilic esophagitis trials each delivered positive secondary or post hoc results, and a post-exposure COVID-19 antiviral's supporting phase 3 data rounded out the month.
Related to this article
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.
Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
FDA approves Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten becomes the first cardiac myosin inhibitor approved for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
Advertisement
Advertisement